Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device Combination Product - ChronoDose

Trial Convincingly Proves Functionality in Humans of CTI's Programmable, Pulsatile, Passive Transdermal Drug Delivery Device - ChronoDose

BASEL, Switzerland and TRENTON, N.J., May 03, 2007 /PRNewswire/ -- Chrono Therapeutics Inc. (CTI) announced today the successful completion of its first phase human clinical trial of its programmable, pulsatile, passive transdermal drug/device combination product: ChronoDose(TM). CTI intends to publish this clinical data in leading scientific and medical journals by year end.

CLINICAL STUDY DESIGN

The trial was conducted between February and April 2007 at the University Hospital Basel, Switzerland, Division of Clinical Pharmacology and Toxicology. Georgios Imanidis, PhD, of the University of Basel was the Principal Investigator on behalf of CTI.

This study was an open, randomized, three period, single-center, dose- escalation study. Thirty-six independent human transdermal tests were conducted on male volunteers using wristwatch-like ChronoDose(TM) devices. The trial successfully proved the efficacy of the device on human subjects using its model drug compound. The dose escalation trial showed statistically significant modulation and control of the dosing profiles. Using low, medium and high concentrations, for 16 hours, the model drug permeated each subject's skin on multiple occasions, resulting in clear and distinct peaks and troughs of therapeutically effective and well-targeted blood plasma concentration levels. A non-compartmental and compartmental model based analysis of pharmacokinetics will be utilized. Local and systemic tolerability of the model drug after its transdermal administration was better than planned.

Dr. Georgios Imanidis commented, "CTI has for the first time in transdermal drug delivery history successfully completed a significant human trial with a passive, automated and programmable multiple dosing transdermal device system. We are extremely pleased with the excellent results".

Guy DiPierro, CEO and President of CTI noted, "This solid and convincing clinical data along with initial human data generated last summer will help us to rapidly commercialize our initial drug product. We are particularly pleased that ChronoDose(TM) produced targeted blood plasma concentrations as accurately as it did and at the intended time periods."

    ABOUT CHRONO THERAPEUTICS INC.

    -- Chrono Therapeutics Inc. (CTI) was founded in late 2003 to become the

       global leader in Chrono-Pharmacologically based prescription and OTC

       drug delivery.

    -- Today CTI is a specialty pharmaceutical company that developing,

       manufacturing and commercializing Chrono-Pharmacologically based drug

       products.

    -- CTI has created and patented the world's first automated and

       programmable, passive transdermal drug delivery device-ChronoDose(TM)

    -- ChronoDose

        -- Dramatically improves therapies

        -- Significantly decreases symptoms and side effects

        -- Ensures less built-up tolerance to the drug

PATIENT NON-COMPLIANCE

Annually, over 20% of hospital admissions result from patient non-compliance, costing the healthcare industry over $100 billion/year. ChronoDose(TM) offers a revolutionary step forward in guaranteed patient compliance, especially for the elderly, hospitalized, or the mentally ill.

    Contact:

    Chrono Therapeutics Inc.

    Guy DiPierro, President and Chief Executive Officer

    Phone: (609) 838 2572

    Email: 

    Website: ChronoDose.com

Info@ChronoDose.com

CONTACT: Guy DiPierro, President and Chief Executive Officer of ChronoTherapeutics Inc., +1-609-838-2572, Info@ChronoDose.com

Web site: http://www.chronodose.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: May 2007

View comments

Hide
(web1)